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Chronic diabetic complications in Africa
Well-conducted epidemiological data regarding chronic 
diabetic complications in Africa are limited. Most reports 
have small samples derived from tertiary referral clinics, 
underlining the need for larger scale community-based 
studies.  However, there is little doubt that the prevalence 
of complications has increased in keeping with the rising 
occurrence of diabetes. This is likely to strain the health 
budgets of often resource-poor countries. For example, 
a recent estimate in Tanzania showed that treatment of 
diabetic complications represented 31% of total outpatient 
costs in the main hospital in Dar es Salaam, with a yearly 
cost of $138 per person; 19 times more than the  average.1
Retinopathy
Mbanya and Sobngwi2 looked at data for the preva-
lence of diabetic complications in Africa and reported 
that retinopathy was present in 16–55% of people with 
diabetes. About a quarter of newly diagnosed type 2 
patients present with retinopathy, and severe retinopathy 
represented 15% of all cases.2 Perhaps not surprisingly, 
duration of diabetes and glycaemic control were found to 
be major determinants of retinopathy.2 In another review 
of diabetic complications in Africa, Sidebe3 reported that 
more than half of the patients with type 2 diabetes had 
retinopathy, and retinopathy accounted for 32% of all eye 
complications. He suggested that differences observed 
in patients with varying ethnic origins may be linked 
primarily to unfavourable social and economic condi-
tions that worsen the risk of poor blood glucose control.3 
In a study involving 300 randomly selected black 
African patients from primary care in Cape Town, South 
Africa, the prevalence of any grade of retinopathy was 
55% – proliferative and pre-proliferative retinopathy 
16%, and cataracts 8%.4 In most cases the complications 
were not documented in the clinic records of the preced-
ing year. The high prevalence of suboptimal glycaemic 
and blood pressure control, as well as complications of 
diabetes largely unrecorded in the preceding year’s clinic 
notes, demonstrates the deficiency of and the need for 
preventative diabetes care at primary care level.4 Another 
study,5 comparing microvascular complications in black 
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and Indian South Africans, showed a high prevalence of 
retinopathy at 53% (blacks 56%, Indians 45%). Onset of 
retinopathy from the time of diabetes diagnosis occurred 
about 5 years earlier in blacks compared with Indians. 
The prevalence of hypertension was much higher in 
blacks than Indians (42% vs 9%, p<0.5), though this 
marked difference may in part be due to the small size 
of the study.5
Rotimi et al6  looked at the prevalence and risk factors 
for diabetic retinopathy and cataracts in 840 patients with 
type 2 diabetes and 191 spouse controls, enrolled from 7 
centres in Ghana and Nigeria. In this cohort (whose mean 
age was 46 years), the prevalence of diabetic retinopathy 
was 18%. Cataracts were present in 45% of patients with 
type 2 diabetes, and in 18% of spouse controls. The risk 
of developing retinopathy increased more than 3-fold for 
patients with the highest fasting plasma glucose (FPG) 
level (odds ratio (OR)=3.4), compared with patients at 
the lowest FPG level.6 The OR for persons with diabetes 
of 10 years or more, compared with persons with dia-
betes for less than 5 years, was 7.3 for retinopathy, and 
2.6 for cataract.6 They concluded that cataracts were a 
more important cause of visual impairment than diabetic 
retinopathy in this cohort. In addition, the prevalence 
of cataract in patients with diabetes was more than 
twice that of their spouse controls, indicating that type 
2 diabetes was an important risk factor for cataract for-
mation. Individuals who developed type 2 diabetes at 
an earlier age were more likely to develop both diabetic 
retinopathy and cataracts. A strong positive association 
was observed between FPG level, duration of diabetes, 
and risk of retinopathy and cataract, underlining the 
need for early eye examination at first presentation of 
elevated blood glucose.6
The diabetic foot, diabetic neuropathy and 
peripheral vascular disease 
Abbas and Archibald7 looked at published data regard-
ing the diabetic foot in Africa, encompassing the years 
1960–2003. Perhaps not surprisingly, foot ulceration and 
infection were associated with considerable long-term 
disability and premature mortality.7 Rates of complica-
tions varied by country, e.g. foot ulcers 4–19%, peripheral 
neuropathy 4 to 84%, peripheral vascular disease 3–79%, 
gangrenous foot ulcers 0.6–69%, and foot amputation 
rates 0.3–45%. They cited a study of diabetic patients 
in Tanzania that showed mortality rates of over 50% 
among patients with severe foot ulcers who did not 
undergo surgery.8
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America have shown diabetic peripheral neuropathy to 
be one of the most common complications of diabetes, 
occurring in 28–55% of diabetic patients9–11, and appears 
to be influenced by age, duration of diabetes, glycae-
mic control; and traditional markers of macrovascular 
disease such as smoking, hypertension, obesity, and 
hyperlipidaemia.12 Though there are few studies that are 
well designed and examine the prevalence or incidence 
of peripheral neuropathy in Africa, there is little doubt 
that neuropathy is the strongest risk factor for foot ul-
ceration and amputation worldwide, including in the 
African setting.13,14 It is indeed the most frequent cause of 
prolonged hospital admission in diabetic patients,14 and 
is a significant contributor to the considerable morbidity 
associated with the diabetic foot.  
There is some variation in the epidemiology of the 
diabetic foot problems in Africa, largely reflecting dif-
fering criteria for data collection, and this is particularly 
problematic for peripheral neuropathy. Table 1 shows the 
range of occurrence of peripheral neuropathy, mainly as a 
result of differing criteria for the definition of neuropathy, 
methods of assessment and selection bias.7 However, it is 
clear that regardless of this, neuropathy is very common.
Peripheral vascular disease (PVD)  
Foot complications in Africa are mainly as a result of 
infection in the neuropathic foot rather than due to 
PVD.7,15–17 However, the rapid urbanisation of communi-
ties across Africa is having an increasing impact on the 
prevalence of macrovascular disease, including PVD. A 
study from Nigeria reported evidence of PVD in 54% 
of diabetic patients with foot complications,18  whilst 
another more recent study from Tanzania found PVD 
in 21% of diabetic patients.8 Table 2 shows rates of PVD 
in different parts of Africa.7 As with neuropathy, there 
is a great variability, in the rates reported, partly due to 
assessment differences. Although neuropathy is often the 
initiating factor for foot ulceration, ischaemia is critically 
important in determining healing. Abbas and colleagues 
have reported the prevalence of neuroischaemic lesions 
in diabetes patients in Tanzania at about 17%.18 Unfortu-
nately, despite a relatively low prevalence rate of PVD in 
diabetic patients with foot ulcers in Africa, amputation is a 
frequent outcome mainly due to uncontrolled infection.7
Foot ulceration    
In Africa, as in the rest of the world, peripheral neu-
ropathy is the main risk factor in the pathogenesis of 
foot ulceration in diabetic patients.15 A Nigerian study19 
reported that 15% of diabetic hospital admissions were 
due to foot ulcers, with 80% of these being first time oc-
currences.  Unfortunately, despite the low prevalence 
rate of PVD, amputation was an outcome in a third of 
patients and was associated with progressive infection. 
and/or missed neuroischaemic lesions. The highest 
inpatient mortality rate (50%) was observed in patients 
with severe foot ulcers whose management did not in-
clude surgery with amputation.19 Overwhelming sepsis 
related to the severe foot infections may explain these 
high rates of mortality. This study also reported that there 
were major issues with regard to obtaining consent for 
minor or major amputations of often severely affected 
limbs,19 mainly due to cultural factors where a loss of 
limb was considered to be worse than a loss of life.13,18 
Several factors have been identified as greatly increasing 
the risk of ulceration and amputation,18,20 as well as the 
traditional risk factors of neuropathy and PVD:  
(a) poverty and barefoot walking; 
(b) inappropriate footwear; 
(c) poor foot hygiene;
(d) delay in seeking medical attention.  
In addition, there have been reports of rat bites on 
the toes of people who sleep on the floor or outdoors.21
Perhaps the most important intervention for the pre-
vention of diabetic foot complications is education of 
the patient about appropriate foot care. With the estab-
lishment of foot clinics, major amputations have been 
generally reduced in western countries. Patients with 
foot lesions are seen either in a multidisciplinary Foot 
Clinic or a Podiatry Led Clinic (for neuropathic ulcers), 
and treated early with antibiotics, removal of callus, and 
given appropriate advice regarding footcare etc. In most 
African countries the situation is different, and these low-
cost clinics run by podiatrists (and possibly nurses with 
some training) are not available. Such clinics, adapted 
to the African situation, could result in a reduction of 
foot-related hospital admission and the prevention of 
major amputations. Abbas and Archibald suggest two 
important patient rules – regular foot inspection and 
making an effort not to walk barefoot – for the preven-
tion of foot problems in Africa.7 They go on to suggest 
that the prevention of peripheral neuropathy through 
Year    Country   Patient number Neuropathy rate
2003	 Zambia	 	 	 185	 	 		 61%
2000	 Tanzania	 	 	 200	 	 		 26%
1997	 South	Africa	 	 300	 	 		 28%
1996	 Uganda	 	 	 252	 	 		 46%
1995	 Ethiopia	 	 	 		43	 	 		 50%
1995	 Sudan	 	 	 128	 	 		 37%
1991	 Malawi	 	 	 100	 	 		 59%
1990	 Nigeria	 	 	 		50	 	 		 68%
Table 1  Prevalence of  diabetic neuropathy in Africa7
Year      Country Patient number PVD rate
2003	 Zambia	 	 185	 	 	 41%
2002	 Tanzania	 	 		92	 	 	 21%
1997	 South	Africa	 	300	 	 	 		8%
1995	 Ethiopia	 	 		43	 	 	 12%
1995	 Sudan	 	 128	 	 	 10%
1991	 Malawi	 	 100	 	 	 15%
1990	 Nigeria	 	 		50	 	 	 54%
Table 2  Prevalence of peripheral vascular disease (PVD) 
amongst diabetic patients in Africa7
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aggressive glycaemic control may be the single most 
important  primary preventative measure for lower limb 
ulceration or infection.7 Early diagnosis of peripheral 
neuropathy and PVD and diabetic foot education may 
also go a long way in reducing the prevalence of foot 
ulceration and amputation.7
Diabetic nephropathy
Diabetic nephropathy is the leading cause of end-stage 
renal disease in the Western world.22–24 Published data 
on nephropathy in the African diabetic population are 
scarce.22 However, there appears to be a racial difference 
in the prevalence of diabetic nephropathy and end-stage 
renal failure. For example, African-American patients 
have been reported to have a greater risk of diabetic 
nephropathy and kidney damage than their Caucasian 
counterparts.25 Over the past three decades, the preva-
lence of microalbuminuria in African diabetic patients 
has varied greatly26–29 (see Table 3). A recent study also 
suggests that diabetic nephropathy may be assuming 
an increasing role as a cause of chronic kidney disease 
in Africa.30 
In a recent study by Lutale and colleagues of microal-
buminuria among type 1 and type 2 diabetic patients of 
African origin in Dar es Salaam, the overall prevalence of 
microalbuminuria was 11% and macroalbuminuria 5%.22 
In type 1 patients, microalbuminuria was present in 12% 
and macroalbuminuria in 1%. Among type 2 patients, 10% 
had microalbuminuria and 7% had macroalbuminuria. 
Type 2 patients with abnormal albumin excretion rates 
had a significantly longer duration diabetes (7.5 years, 
range 0.2–24 years) than those with a normal albumin 
excretion rate (3 years, range 0–25 years, p<0.001). Systolic 
and diastolic blood pressure among type 2 patients with 
microalbuminuria were significantly higher than those 
without (p<0.001).22 The most significant differences 
seen in body mass index, glycaemic control, and cho-
lesterol levels were found among patients with normal 
compared with those with elevated albumin excretion 
rates, either in type 1 or type 2 diabetes. However a 
stepwise multiple linear regression analysis among type 
2 patients revealed duration of diabetes, systolic blood 
pressure, and serum creatinine to be independent risk 
factors. The authors concluded that the prevalence of 
micro- and macroalbuminuria was higher among type 
1 patients with a relatively short diabetes duration, 
compared with the prevalence among Caucasians. In 
type 2 diabetes, the prevalence was in accordance with 
findings in Caucasians. 
Diabetic nephropathy is emerging as a major cause of 
end-stage renal disease (ESRD) in sub-Saharan Africa.30 
The prevalence of diabetic nephropathy as a cause of 
ESRD has also been looked at in north Africa. Afifi 
and colleagues in Egypt31 performed a 6-year multiple 
cross-sectional study between 1996 and 2001, for the 
prevalence of diabetic nephropathy. Prevalence gradually 
increased from 8.9% in 1996 to 14.5% in 2001. The mean 
age of patients with diabetic nephropathy was signifi-
cantly higher than that of patients with ESRD from other 
causes. Mortality was also significantly higher in diabetic 
patients with ESRD.31 Gill and colleagues32 looked at the 
long-term (20 years) mortality, with causes of death, in 
a cohort of type 1 diabetic patients resident in Soweto, 
South Africa. They found, leaving aside those lost to 
follow-up, that most mortality was as a result of renal 
failure related to diabetic nephropathy. They concluded 
that this reflected the lack of adequate facilities for renal 
replacement therapy in Africa. Another study from South 
Africa has also shown that renal failure in type 2 diabetic 
patients is a major cause of death.33 
A study from Nigeria looked at the distribution of 
cardiovascular risk factors among subjects with type 
2 diabetes and nephropathy, since in nephropathy the 
excess mortality is mainly cardiovascular.34 They found 
that there was a high prevalence of cardiovascular risk 
factors among Nigerian subjects with clinical diabetic 
nephropathy.34 Another study from Nigeria identified 
patients with diabetic nephropathy as a high-risk group 
for excess cardiovascular morbidity.35
Coronary artery disease
Kengne and colleagues have recently reviewed cardio-
vascular complications of diabetes in sub-Saharan Africa.36 
The lack of diagnostic facilities limits studies in coronary 
heart disease (CHD) in sub-Saharan Africa,36 as coronary 
angiography and myocardial scintography are available 
only in a few urban health facilities. However, ischaemic 
heart disease was considered to be rare in Africa two 
decades ago,36 yet is now regularly seen.36 
Ischaemic heart disease may be present at the clinical 
onset of diabetes in up to 5% of patients.37 A study from 
Ghana reported that 80% of subjects with cardiovascular 
disease presenting to a major cardiac referral centre had 
CHD.38 Compared with subjects with other cardiovas-
cular disorders, those with CHD were older and had a 
higher  incidence of hypertension (66%). Nearly a quarter 
had diabetes.38 In a study from Cameroon, CHD ranked 
eighth among cardiovascular diseases, with a prevalence 
of 1.5%.39   Myocardial infarction (43%), predominantly 
anterior (73%), was the most frequent clinical form of 
CHD observed. Obesity (80%), hypertension (60%), hy-
perlipidaemia (43%), smoking (36%), and diabetes (26%) 
Year Country Patient number Microalbuminuria rate
2006	 Tanzania	 		91	type	1	 12%	(type	1)
	 	 	 153	type	2		 10%	(type	2)
2002	 Kenya		 100	type	2	 26%	(type	2)
1999	 Cameroon	 		64	mixed	 53%
1997	 Ethiopia	 		71	type	1	 32%	(type	1)
	 	 	 		99	type	2	 37%	(type	2)
1992	 Nigeria	 113	type	2	 57%	(type	2)
Table 3  Prevalence of microalbuminuria in diabetes 
patients in Africa7
Review Article
African Journal of Diabetes Medicine 7  Vol 19 No 1 May 2011
were the major risk factors reported in the study. Three 
-quarters of the patients had at least three risk factors.  
In East Africa, a Sudanese study reported that CHD 
(at 28%) was the most frequent macrovascular compli-
cation of diabetes, followed by PVD (10%) and stroke 
(5%).40 In a dual-armed study, consisting of retrospective 
and prospective comparative arms, black Kenyans who 
underwent coronary angiography were studied. The 
risk factors found to be most strongly associated with 
the presence of angiographically detected CHD were 
diabetes, dyslipidaemia, age, and male gender. There 
was a high prevalence of  hypertension, which was not 
predictive of CHD.41 Cigarette smoking was uncommon 
in most surveys. In a study of 139 patients from Dar es 
Salaam, using clinical and resting electrocardiogram 
(ECG) parameters, findings compatible with ischaemic 
heart disease were found in 34% patients, and in 6% the 
ECG changes were classified as ‘probable ischaemia’.42 
Cerebrovascular disease
Epidemiological data on cerebrovascular disease in Af-
rica have been scarce because of the low proportion of 
patients presenting to hospitals, the high mortality rate, 
and inaccuracies and deficiencies in death certification. 
In Tanzania, regular censuses of three surveillance popu-
lations consisting of 307 820 people (125 932 aged below 
15 years and 181 888 aged 15 or more) were undertaken 
with prospective monitoring of all deaths arising in these 
populations between 1992 and 1995.43 During the 3-year 
observation period 11 975 deaths were recorded in the 
three areas, of which 7629 (64%) were in adults (54% of 
these in men and 46% in women). In these adults, 5.5% 
of the deaths were attributed to cerebrovascular disease, 
53% of these in men and 47% in women. The yearly age-
adjusted rates per 100 000 in the 15–64 year age group for 
urban dwellers were 65 for men, and 88 for women, as 
compared with the England and Wales (1993) rates of 11 
for men and 9 for women. These high rates in Tanzania 
were probably due to untreated hypertension. In this 
study 4.4% of type 2 diabetic  patients presented with 
stroke at diagnosis of diabetes.43 
At a hospital in Burkina Faso, cerebrovascular disease 
accounted for 15% of admissions for cardiovascular 
disorders, and of these 72% of patients had low incomes 
and 22% were labourers. The major risk factors were 
poorly controlled hypertension (84%), obesity (44%), 
hyperlipidaemia (21%), thromboembolism (17%), smok-
ing (12%), hypercholesterolemia (8%) and diabetes (7%). 
The authors emphasised the need for improvement in 
the management of hypertension by district physicians.44 
In an early study from Zambia of 600 diabetic patients, 
Rolfe reported a 1.2% stroke rate.45 In a more recent 
prospective study of type 2 diabetic Nigerians, stroke-
associated death occurred in 8%. All the stroke-related 
deaths occurred in the hypertensive group.46 Male pa-
tients also appeared to have a significantly enhanced 
risk of stroke-related deaths.   
Diabetes-related cardiovascular complications are 
becoming more prevalent in Africa. Currently, most 
available resources are being channelled to fighting com-
municable diseases such as HIV/AIDS and TB. However, 
the burden of diabetic complications will continue to rise 
unless systems are in place to tackle this tide. 
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